The stock of Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) is a huge mover today! About 244,094 shares traded hands. Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) has risen 6.08% since April 14, 2016 and is uptrending. It has outperformed by 1.40% the S&P500.
The move comes after 9 months negative chart setup for the $8.05B company. It was reported on Nov, 16 by Barchart.com. We have $43.41 PT which if reached, will make NYSE:RDY worth $563.50 million less.
Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) Ratings Coverage
Out of 5 analysts covering Dr. Reddy’s (NYSE:RDY), 0 rate it a “Buy”, 3 “Sell”, while 2 “Hold”. This means 0 are positive. Dr. Reddy’s has been the topic of 5 analyst reports since November 10, 2015 according to StockzIntelligence Inc. Deutsche Bank initiated the shares of RDY in a report on Wednesday, December 2 with “Sell” rating. The stock of Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) has “Neutral” rating given on Monday, May 2 by Goldman Sachs. The firm has “Underperform” rating given on Wednesday, July 27 by Jefferies. The stock of Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) has “Neutral” rating given on Tuesday, November 10 by Citigroup. On Wednesday, July 27 the stock rating was downgraded by HSBC to “Reduce”.
According to Zacks Investment Research, “Doctor Reddy’s is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection”
More recent Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) news were published by: Marketwatch.com which released: “Dr. Reddy’s Laboratories Ltd. ADR” on January 20, 2010. Also Fool.com published the news titled: “Dr. Reddy’s Laboratories Ltd (ADR) Is Tanking Today — Here’s Why” on July 26, 2016. Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 11, 2011 was also an interesting one.
RDY Company Profile
Dr. Reddy’s Laboratories Limited, incorporated on February 24, 1984, is a pharmaceutical firm that is engaged in providing medicines. The Firm operates in three divisions: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities (NCEs). These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC. Others include the activities of its subsidiary, Aurigene Discovery Technologies Limited, a discovery-stage biotechnology firm developing therapies in the fields of oncology and inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.